Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of B...
15 Junio 2015 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel protein therapeutics for cancer and rare
diseases, today announced that new study findings involving the use
of dalantercept to block the activin receptor-like kinase 1 (ALK1)
pathway for the treatment of metastatic breast cancer were
published in the June 15th issue (volume 75, #12) of Cancer
Research, a journal of the American Association for Cancer
Research. These pre-clinical findings suggest that dalantercept, in
addition to treating the primary tumor, may also have an effect on
metastasis, the principal clinical issue in advanced disease.
Breast cancer patients with high levels of the ALK1 in the blood
vessels of their tumor are more likely to develop metastatic
disease according to the research led by Kristian Pietras, Ph.D.,
the Goran and Birgitta Grosskopf Professor of Molecular Medicine at
Lund University in Sweden.
“Although prognosis for breast cancer is relatively good when
detected in its early stages, metastatic disease is the cause of
90% of all cancer-related deaths. Therefore, learning more about
the metastatic process and finding new cures to inhibit the
advancement of metastatic disease is a clinical priority,” said Dr.
Pietras. “The role of ALK1 expression by endothelial cells in
primary breast tumor vasculature is a prognostic biomarker for
metastatic dissemination. We used dalantercept to inhibit ALK1 in
multiple mouse models of breast cancer, and in doing so, we were
able to prevent metastatic dissemination and specifically the
spread of the primary breast tumor to the lungs.”
The study publication is available on Acceleron’s website
(www.acceleronpharma.com) in the Publications section.
About Dalantercept
Dalantercept (ACE-041) is an investigational protein therapeutic
that inhibits angiogenesis by preventing BMP9, a protein in the
Transforming Growth Factor-Beta (TGF-Beta) superfamily, from
interacting with activin receptor-like kinase 1 (ALK1), a
cell-surface receptor found on proliferating vascular endothelial
cells. Dalantercept inhibits ALK1 signaling, which is required for
the development of mature, functional vasculature. Dalantercept is
being investigated in a randomized placebo-controlled Phase 2 study
in combination with axitinib in patients with advanced renal cell
carcinoma and in a Phase 1b open-label study in combination with
sorafenib in patients with advanced hepatocellular carcinoma.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases. The company is a
leader in understanding the biology of the TGF-Beta protein
superfamily, a large and diverse group of molecules that are key
regulators in the growth and repair of tissues throughout the human
body, and in targeting these pathways to develop important new
medicines. Acceleron has built a highly productive R&D platform
that has generated innovative clinical and preclinical protein
therapeutic candidates with novel mechanisms of action. These
protein therapeutic candidates have the potential to significantly
improve clinical outcomes for patients with cancer and rare
diseases.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements about
Acceleron's strategy, future plans and prospects, including
statements regarding the development and potential future efficacy
of dalantercept. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statement.
Applicable risks and uncertainties include that preclinical testing
of Acceleron's compounds and data from clinical trials may not be
predictive of the results or success of ongoing or later clinical
trials, that data may not be available when we expect it to be,
that Acceleron will be unable to successfully complete the clinical
development of its compounds, that the development of Acceleron's
compounds will take longer or cost more than planned, that
Acceleron may be delayed in initiating or completing any clinical
trials, and that Acceleron's compounds will not receive regulatory
approval or become commercially successful products. Other risks
and uncertainties include those identified under the heading "Risk
Factors" included in Acceleron's Annual Report on Form 10-K which
was filed with the Securities and Exchange
Commission (SEC) on March 2, 2015, and other filings that
Acceleron has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release reflect Acceleron's current views with respect to future
events, and Acceleron does not undertake and specifically disclaims
any obligation to update any forward-looking statements.
For more information, please visit www.acceleronpharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150615005422/en/
Acceleron PharmaSteve Ertel, 617-649-9234Executive Vice
President and Chief Operating OfficerorMedia:Suda Communications
LLCMaureen L. Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024